Corporate Profile

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.
Featured Documents
1/12/20
January 2020 Corporate Presentation

Share Price

Price
Change (%)  (%)
Volume
Data as of

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events
There are currently no events scheduled.
Recent News
La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
1/9/20
SAN DIEGO , Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced
Read More →
La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
11/25/19
SAN DIEGO , Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it
Read More →
La Jolla Pharmaceutical Company Announces Management Transition
11/25/19
SAN DIEGO , Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →